SciSparc Ltd. SPRC
SciSparc Ltd. (Nasdaq: SPRC) is a CNS/neurology/psychiatry drug developer. Its lead program, SCI-110 (THC + PEA/CannAmide), is in Phase 2 for Tourette syndrome; Alzheimer's disease agitation.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SCI-110 | Tourette syndrome (Phase IIa completed; Phase IIb approved in Germany/Israel and FDA IND cleared Oct 2024, not started) | small molecule | Phase 2 |
| SCI-110 | Alzheimer's disease agitation (Phase IIa open-label completed, topline June 2023) | small molecule | Phase 2 |
| SCI-210 (CBD + PEA/CannAmide) | autism spectrum disorder; status epilepticus | small molecule | Pre-clinical |
Recent results and decisions
- Oct 23, 2026n/a NeuroThera Labs completed manufacturing of SCI-110 investigational product and obtained European QP batch release certification for Phase IIb Tourette Syndrome trial, with all three clinical sites ready for patient enrollment.
NeuroThera has successfully completed the manufacturing of the investigational product and obtained the required batch release certification from a European Qualified Person.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.